Glycan Biosciences, a product focused biotechnology company, has a proprietary carbohydrate-based chemistry platform to produce a novel class of new chemical entities (NCEs) called Glycanics. Glycanics uniquely can modulate multiple protein-protein interactions involved in inflammatory diseases. In addition, the technology allows tailoring of Glycanics to differentially modulate activity of multiple target proteins of interest.